Spotlight on Internal Medicine

Credits: 0.25 CME / MOC
MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – PSA
Grace C. Wright, MD, PhD, FACR
Vindico

MedEdTalks Rheumatology: 3rd Annual Association of Women in Rheumatology National Conference: Immunology Bootcamp – PSA

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: October 28, 2019
Expires: October 27, 2020
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
  • Select treatment for patients with IMID based on the latest clinical evidence and patient characteristics.

Activity Description

In this CME podcast, Dr. John Tesser and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of psoriatic arthritis (PsA).

Faculty

Activity Chair
Grace C. Wright, MD, PhD, FACR
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB


Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB


Jeffrey L. Kaine, MD
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer


John R.P. Tesser, MD
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, October 28, 2019 to October 27, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: October 28, 2019
Expires: October 27, 2020
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the management of patients with immune-mediated inflammatory diseases (IMIDs).

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate common signaling pathways that underly chronic immune-mediated inflammatory conditions as well as the molecular targets of available and emerging immune-based therapies.
  • Select treatment for patients with IMID based on the latest clinical evidence and patient characteristics.

Activity Description

In this CME podcast, Dr. John Tesser and Dr. Jeffrey Kaine will discuss the diagnosis and treatment of psoriatic arthritis (PsA).

Faculty

Activity Chair
Grace C. Wright, MD, PhD, FACR
President and CEO, Grace C. Wright, MD PC
President, Association of Women in Rheumatology
New York, NY
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Exagen, Lilly, Myriad, Novartis, Pfizer, Sanofi Genzyme/Regeneron, UCB


Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, Horizon, Janssen, Lilly, Pfizer, Sanofi-Regeneron, UCB


Jeffrey L. Kaine, MD
Independent Healthcare Associates, Inc.
Cullowhee, NC
Disclosures
Consulting Fee: AbbVie, Gilead, Lilly, Novartis, Pfizer
Speakers Bureau: Bristol-Myers Squibb, Lilly, Merck, Pfizer


John R.P. Tesser, MD
Adjunct Clinical Professor
Midwestern University College of Health Sciences
Arizona Arthritis and Rheumatology Associates, P.C.
Phoenix, AZ
Disclosures
Consulting Fee: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Gilead, Janssen, Lilly, Medac, Novartis, Pfizer, Samumed, Sanofi Genzyme/Regeneron, UCB
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Crescendo Biosciences/Myriad, Genentech, Janssen, Lilly, Medac, Pfizer, Regeneron, Sanofi Genzyme/Regeneron, UCB
Contracted Research: AbbVie, Ablynx, Amgen, AstraZeneca, Aurinia, Biogen, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eicos, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Lilly, Mallinckrodt, Merck KG, Novartis, Pfizer, R-Pharma, Regeneron, Roche, Samumed, Sandoz, Sanofi Genzyme/Regeneron, Setpoint, Sun, Takeda, UCB
Innovation Theater Presentation: Lilly, Sanofi Genzyme/Regeneron


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
No relevant financial relationships to disclose.

Staff
Vindico Medical Education
No relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, faculty, reviewers, and staff involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Signed Disclosure(s) are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

This enduring material is approved for 1 year from the date of original release, October 28, 2019 to October 27, 2020.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest question, listen to the presentation, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by educational grants from AbbVie, Inc.; Amgen Inc.; Bristol-Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Lilly USA, LLC; Merck & Co., Inc.; and Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?
Contact us at CME@VindicoCME.com

Internal Medicine Presentations

0.25 CME
Medical Education Resources (MER)
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Vision-Saving Treatments for Patients With Diabetes

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Vision-Saving Treatments for Patients With Diabetes

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 19, 2020
Expires: June 19, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Treatments for DME
  • Treatments for DR
  • Types of anti-vascular endothelial growth factor (VEGF) drugs
  • Important considerations in anti-VEGF therapy

Faculty

W. Lloyd Clark, MD
Retina Specialist with Palmetto Retina Center
West Columbia, SC


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

W. Lloyd Clark, MD, has disclosed grant research funded by Genentech, Regeneron, and Roche. Additionally, he has received consulting fees from and speaks on speaker bureaus for Genentech, Regeneron and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 19, 2020
Expires: June 19, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Treatments for DME
  • Treatments for DR
  • Types of anti-vascular endothelial growth factor (VEGF) drugs
  • Important considerations in anti-VEGF therapy

Faculty

W. Lloyd Clark, MD
Retina Specialist with Palmetto Retina Center
West Columbia, SC


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

W. Lloyd Clark, MD, has disclosed grant research funded by Genentech, Regeneron, and Roche. Additionally, he has received consulting fees from and speaks on speaker bureaus for Genentech, Regeneron and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

0.25 CME
Medical Education Resources (MER)
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Unmet Eye Care Needs in Diabetes Mellitus

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: May 15, 2020
Expires: May 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™ and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Growing incidence of diabetes
  • Diabetic retinopathy—a leading cause of blindness
  • Lack of awareness of eye disease risk among patients with diabetes
  • Dilated eye exam recommendations and frequency
  • Management and follow-up obstacles

Faculty

Carl D. Regillo, MD, FACS
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Carl D. Regillo, MD, FACS, has disclosed grant research funded by Allergan, Genentech, Novartis, Regeneron, Kodiak, Chengdu Kanghong, Opthea, Adverum, RegenxBio, and Graybug. Additionally, he has received consulting fees from Allergan, Genentech, Novartis, Chendu Kanghong, Kodiak, Adverum, and Graybug. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

1.00 CME
Forefront Collaborative
Exploring Within: A Mixed Reality Look Into Migraine and Episodic Cluster

Exploring Within: A Mixed Reality Look Into Migraine and Episodic Cluster

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 13, 2020
Expires: April 13, 2021
60 minutes to complete

Accredited By

Target Audience

The target audiences are headache specialists and PCPs. Other healthcare professionals who treat patients with migraine, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, may benefit from participation.

Learning Objectives

Upon completion of this activity, participants should be able to

  • Apply concepts in migraine pathophysiology and therapeutic mechanism of action (MOA) to treatment discussions
  • Develop treatment plans in line with current standards of practice and guidelines for the management of migraine and episodic cluster headache (eCH)
  • Effectively communicate with patients using shared decision making (SDM) to diagnose and treat headache disorders
  • Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine and eCH
  • Discuss burden of migraine and eCH and impact to quality of life (QoL)

Activity Description

Delve deep into the scientific advances in migraine and episodic cluster headache (eCH) through a mixed reality experience as faculty demonstrate the intricacies of acute and preventive treatments with a HoloLens device. This CME presentation features a case series and faculty discussion to strengthen expertise in treating migraine and eCH to alleviate patient burden and improve their quality of life.

Statement of Educational Need

The burst of mechanism-specific treatments for migraine prevention has transformed lives of patients and may do the same for those with episodic cluster headache. New challenges face healthcare professionals, managing the use of therapies antagonizing the calcitonin gene-related peptide system and readying for the next evolution of acute migraine treatments, including ditans and gepants.

Agenda

  • Welcome and Session Overview
  • Pathophysiology and Mechanism of Action Depicted in Mixed Reality
  • Cases in Episodic Migraine and Episodic Cluster Headache
  • Question and Answer Session
  • Adjournment

Faculty

Merle L. Diamond, MD
President and Managing Director,
Diamond Headache Clinic
Chicago, Illinois


Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Wade M. Cooper, DO
Associate Professor of Neurology,
Michigan Medicine
Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of recording.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planner (Forefront Collaborative): Sydney Pate, MS
  • Planner (Shared Decision Making): Sarina Schrager, MD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Planner (SDM Table)**: Jessica Ailani, MD, has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, ElectroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen
  • Planner (HoloLens)**: Rami Burstein, PhD, has received a consulting fee for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Lilly, Novartis, and Teva Pharmaceutical Industries; he has participated in an advisory board for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Novartis, Revance, and Teva Pharmaceutical Industries; Dr. Burstein has contracted research from Allergan, Dr. Reddy’s, and Teva Pharmaceutical Industries
  • Planner (Forefront Collaborative):Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
  • Presenter: Merle Diamond, MD, has consulted for Alder BioPharmacuticals, Amgen, Eli Lilly & Co., Promius Pharma, Teva Pharmaceutical Industries Ltd.; she has participated in a speaker’s bureau for Amgen, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.; Dr. Diamond has participated in an advisory board for Alder BioPharmacuticals, Amgen, Assertio Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories
  • Presenter: Wade Cooper, DO, has consulted and participated in an advisory board for Alder, Amgen, Eli Lilly, Lundberg, and Teva
  • Presenter: Stewart Tepper, MD, has grants for research with no personal compensation from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; he has consulted for Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; Dr. Tepper participated on an advisory board for Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano; Dr. Tepper has stock options in Percept; he receives salary from Dartmouth-Hitchcock Medical Center and the American Headache Society

**Disclosed at the time of original work.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: April 13, 2020
Expires: April 13, 2021
60 minutes to complete

Accredited By

Target Audience

The target audiences are headache specialists and PCPs. Other healthcare professionals who treat patients with migraine, including general neurologists, physician assistants, nurse practitioners, nurses, and pharmacists, may benefit from participation.

Learning Objectives

Upon completion of this activity, participants should be able to

  • Apply concepts in migraine pathophysiology and therapeutic mechanism of action (MOA) to treatment discussions
  • Develop treatment plans in line with current standards of practice and guidelines for the management of migraine and episodic cluster headache (eCH)
  • Effectively communicate with patients using shared decision making (SDM) to diagnose and treat headache disorders
  • Analyze safety and efficacy profiles for new and emerging therapies in acute and preventive treatment of migraine and eCH
  • Discuss burden of migraine and eCH and impact to quality of life (QoL)

Activity Description

Delve deep into the scientific advances in migraine and episodic cluster headache (eCH) through a mixed reality experience as faculty demonstrate the intricacies of acute and preventive treatments with a HoloLens device. This CME presentation features a case series and faculty discussion to strengthen expertise in treating migraine and eCH to alleviate patient burden and improve their quality of life.

Statement of Educational Need

The burst of mechanism-specific treatments for migraine prevention has transformed lives of patients and may do the same for those with episodic cluster headache. New challenges face healthcare professionals, managing the use of therapies antagonizing the calcitonin gene-related peptide system and readying for the next evolution of acute migraine treatments, including ditans and gepants.

Agenda

  • Welcome and Session Overview
  • Pathophysiology and Mechanism of Action Depicted in Mixed Reality
  • Cases in Episodic Migraine and Episodic Cluster Headache
  • Question and Answer Session
  • Adjournment

Faculty

Merle L. Diamond, MD
President and Managing Director,
Diamond Headache Clinic
Chicago, Illinois


Stewart J. Tepper, MD
Professor of Neurology,
Geisel School of Medicine at Dartmouth
Director, Dartmouth Headache Center
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire


Wade M. Cooper, DO
Associate Professor of Neurology,
Michigan Medicine
Director,
Headache and Neuropathic Pain Program
University of Michigan
Ann Arbor, Michigan


Conflict of Interest Policy/Disclosure Statement

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s)*. For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the time of recording.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing health care goods or services consumed by or used on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.

The following individuals have indicated that neither they nor their spouses/partners have had, in the past 12 months, financial relationship(s) with commercial interests relative to the content of this CME activity:

  • Planner (Forefront Collaborative): Sydney Pate, MS
  • Planner (Shared Decision Making): Sarina Schrager, MD

The following individuals have disclosed that they and/or their spouse/partner has had a financial relationship in the past 12 months:

  • Planner (SDM Table)**: Jessica Ailani, MD, has consulted for Allergan, Alder Biopharmaceuticals, Amgen, Lilly, ElectroCore, and Promius; she has participated in a speaker’s bureau for Allergan, Amgen, Avanir Pharmaceuticals, Lilly, ElectroCore, Promius, and Teva Pharmaceutical Industries; Dr. Ailani has participated in an advisory board for Biohaven, Impel, and Satsuma Pharmaceuticals; she has contracted research from Amgen
  • Planner (HoloLens)**: Rami Burstein, PhD, has received a consulting fee for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Lilly, Novartis, and Teva Pharmaceutical Industries; he has participated in an advisory board for Alder Biopharmaceuticals, Allergan, Dr. Reddy’s, Novartis, Revance, and Teva Pharmaceutical Industries; Dr. Burstein has contracted research from Allergan, Dr. Reddy’s, and Teva Pharmaceutical Industries
  • Planner (Forefront Collaborative):Lily Zurkovsky, PhD, has personal stock in Teva Pharmaceutical Industries
  • Presenter: Merle Diamond, MD, has consulted for Alder BioPharmacuticals, Amgen, Eli Lilly & Co., Promius Pharma, Teva Pharmaceutical Industries Ltd.; she has participated in a speaker’s bureau for Amgen, Assertio Therapeutics, Eli Lilly & Co., Supernus Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.; Dr. Diamond has participated in an advisory board for Alder BioPharmacuticals, Amgen, Assertio Therapeutics, Eli Lilly & Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories
  • Presenter: Wade Cooper, DO, has consulted and participated in an advisory board for Alder, Amgen, Eli Lilly, Lundberg, and Teva
  • Presenter: Stewart Tepper, MD, has grants for research with no personal compensation from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Scion Neurostim, Teva, and Zosano; he has consulted for Acorda, Alder, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, Currax, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Revance, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano; Dr. Tepper participated on an advisory board for Acorda, Alder/Lundbeck, Allergan, Amgen, Aralez Pharmaceuticals Canada, Biohaven, Eli Lilly, GSK, Novartis, Pfizer, Satsuma, Teva, Theranica, XOC, and Zosano; Dr. Tepper has stock options in Percept; he receives salary from Dartmouth-Hitchcock Medical Center and the American Headache Society

**Disclosed at the time of original work.

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative and Lilly.

The content of this activity was independently peer reviewed by two reviewers and a patient with migraine. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include reference(s) to unlabeled or unapproved uses of drugs or devices.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

0.25 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Future Therapeutic Approaches

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Future Therapeutic Approaches

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres Therapeutics, Takeda, UCB
  • Speakers Bureau: AbbVie, Janssen, Takeda
  • Unrestricted Educational Grants: AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Miguel Regueiro, MD, AGAF, FACG, FACP
Chair, Department of Gastroenterology and Hepatology
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Vice Chair, Digestive Disease and Surgery Institute
Professor of Medicine
Cleveland Clinic
Cleveland, OH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Miraca Labs, Pfizer, Seres Therapeutics, Takeda, UCB
  • Speakers Bureau: AbbVie, Janssen, Takeda
  • Unrestricted Educational Grants: AbbVie, Janssen, Pfizer, Salix, Shire, Takeda, UCB


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Crohn’s Disease

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Crohn’s Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
  • Disclosures:
  • Royalty: SLACK Incorporated
  • Consulting Fee: AbbVie, Celgene, Cellcuetix, Endo Pharmaceuticals, Ferring, Gilead, Janssen, Lilly, Luitpold/American Regent, Merck, Morphic Therapeutic, Pfizer, Prometheus, Romark, Salix/Valeant, Shire, Takeda, UCB
  • Contracted Research: Celgene, Janssen, Salix/Valeant, Shire, UCB
  • Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
  • Data and Safety Monitoring Board: Lilly
  • Author Honoraria: McMahon Publishing, UpToDate
  • Editor Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
  • Disclosures:
  • Royalty: SLACK Incorporated
  • Consulting Fee: AbbVie, Celgene, Cellcuetix, Endo Pharmaceuticals, Ferring, Gilead, Janssen, Lilly, Luitpold/American Regent, Merck, Morphic Therapeutic, Pfizer, Prometheus, Romark, Salix/Valeant, Shire, Takeda, UCB
  • Contracted Research: Celgene, Janssen, Salix/Valeant, Shire, UCB
  • Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
  • Data and Safety Monitoring Board: Lilly
  • Author Honoraria: McMahon Publishing, UpToDate
  • Editor Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Ulcerative Colitis

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Ulcerative Colitis

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC
  • Disclosures:
  • Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant
  • Speakers Bureau: AbbVie, UCB
  • Contracted Research: Pfizer, Takeda


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC
  • Disclosures:
  • Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant
  • Speakers Bureau: AbbVie, UCB
  • Contracted Research: Pfizer, Takeda


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Utilizing Therapeutic Drug Monitoring

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Utilizing Therapeutic Drug Monitoring

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty Member and Activity Co-chair

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Activity Co-chair

Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty Member and Activity Co-chair

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Activity Co-chair

Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.75 CME
Vindico
What’s New in Flu? Advances in Therapeutic Options

What’s New in Flu? Advances in Therapeutic Options

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME
Vindico
Expanding Options in Influenza Management

Expanding Options in Influenza Management

Start

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: January 13, 2020
Expires: January 12, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based guidelines to diagnose influenza to improve earlier detection and treatment.
  • Compare currently available treatments for influenza based on their efficacy, effect on duration of virus, as well as the ability to improve outcomes for patients at normal and high risk for complications.
  • Implement best practices for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness, viral shedding, and complications associated with the disease.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in 9.2 million to 35.6 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually since 2010. Antiviral agents with different targets and mechanisms of action provide multiple therapeutic options and have promise of improving treatment effectiveness. In this continuing education activity, experts examine how to effectively diagnose and treat patients with influenza.

Faculty

Activity Chair:

Sanjay Sethi, MD
Professor and Chief
Pulmonary, Critical Care and Sleep Medicine
Assistant Vice President for Health Sciences
Department of Medicine
Jacobs School of Medicine & Biomedical Sciences
University of Buffalo
Buffalo, NY

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pulmonx, Pulmotect
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline


Faculty:

William A. Fischer II, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Speaker Honoraria: Genentech


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 13, 2020 to January 12, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.25 AMA PRA Category 1 Credit(s)
Released: January 13, 2020
Expires: January 12, 2021
75 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is pulmonologists and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Utilize evidence-based guidelines to diagnose influenza to improve earlier detection and treatment.
  • Compare currently available treatments for influenza based on their efficacy, effect on duration of virus, as well as the ability to improve outcomes for patients at normal and high risk for complications.
  • Implement best practices for prophylaxis, prevention, and treatment of influenza to reduce the duration of illness, viral shedding, and complications associated with the disease.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention estimates that influenza has resulted in 9.2 million to 35.6 million illnesses, 140,000 to 710,000 hospitalizations, and 12,000 to 56,000 deaths annually since 2010. Antiviral agents with different targets and mechanisms of action provide multiple therapeutic options and have promise of improving treatment effectiveness. In this continuing education activity, experts examine how to effectively diagnose and treat patients with influenza.

Faculty

Activity Chair:

Sanjay Sethi, MD
Professor and Chief
Pulmonary, Critical Care and Sleep Medicine
Assistant Vice President for Health Sciences
Department of Medicine
Jacobs School of Medicine & Biomedical Sciences
University of Buffalo
Buffalo, NY

Disclosure:
Consulting Fee: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pulmonx, Pulmotect
Speakers Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline


Faculty:

William A. Fischer II, MD
Assistant Professor of Medicine
Division of Pulmonary Diseases and Critical Care Medicine
Institute of Global Health and Infectious Diseases
University of North Carolina School of Medicine
Chapel Hill, NC

Disclosure:
Speaker Honoraria: Genentech


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 13, 2020 to January 12, 2021.

How to Participate in this Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

MIPS Qualifying Activity:
Vindico has identified this CME activity as an improvement activity in the Merit-Based Incentive Payment System (MIPS) of the Quality Payment Program (QPP). Participants who successfully complete the activity and its performance assessment will receive printable documentation of successful completion for MIPS self-reporting.

To meet the criteria for improvement activities in the MIPS of QPP, accredited CME providers need to implement activities that:

  • address a quality or safety gap that is supported by a needs assessment or problem analysis, or support the completion of such a needs assessment as part of the activity;
  • have specific, measurable aim(s) for improvement;
  • include interventions intended to result in improvement;
  • include data collection and analysis of performance data to assess the impact of the interventions; and
  • define meaningful clinician participation in their activity, describe the mechanism for identifying clinicians who meet the requirements, and provide participant completion information.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages